Loading candles…
Anthem Biosciences Ltd, incorporated in 2006 as a private limited company and later converted to a public entity, is headquartered in Bengaluru, India. The company operates in the pharmaceutical, biopharmaceutical, and nutritional health industries. It provides contract research, development, and manufacturing organization (CRDMO) services and manufactures specialty ingredients for nutritional and health applications. Anthem Biosciences focuses on niche, high-end manufacturing capabilities, including peptides and high-potent compounds, serving mainly the Indian market. The company holds a significant market position within these specialized manufacturing segments. There are no recorded founders, key management details, subsidiaries, or stock exchange listings associated with the company.
This page is a live market overview for ANTHEM BIOSCIENCES LTD (ANTHEM) on the NSE. As a listed security, ANTHEM BIOSCIENCES LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for ANTHEM before placing trades on tick2trade.
As of the latest feed, ANTHEM last traded at ₹841 on NSE, up ₹15.35 (1.86%) from the previous close of ₹825.65. Today's session range is ₹823.55 – ₹844.9, against a 52-week band of ₹579.15 – ₹873.5. Traded volume today stands at 4.73L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for ANTHEM in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether ANTHEM is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for ANTHEM BIOSCIENCES LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in ANTHEM. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated ANTHEM option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 21 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 19 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 8 Nov 2025 |
| Unaudited Results - Q1-FY25 | Board Meeting intimation for consideration and approval of the Unaudited Consolidated and Standalone Financial Results for the quarter ended Jun 30, 2025 | 13 Aug 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.